Literature DB >> 3115154

Oxygen transport during exercise at extreme altitude: Operation Everest II.

J T Reeves, B M Groves, J R Sutton, P D Wagner, A Cymerman, M K Malconian, P B Rock, P M Young, J K Alexander, C S Houston.   

Abstract

Eight male volunteers had rest and exercise measurement to determine the mechanisms of oxygen transport during a 40-day chamber decompression simulating high-altitude exposure equivalent to the summit of Mt Everest. Five subjects completing the study decreased their maximum oxygen uptake by 72%. During maximal or near-maximal exercise, arterial PCO2 fell as low as 8 mm Hg, defending the alveolar PO2 and confirming marked hyperventilation. Alveolar-arterial diffusion did not improve and V/Q worsened. Cardiac function was unimpaired. Circulatory oxygen transport resembled that at sea level. The decrease in mixed venous PO2 was not enough to preserve fractional oxygen utilization "on the summit." The PO2 gradients from atmosphere to alveolus, alveolus to arterial blood, arterial to venous blood, and from venous (capillary) blood to mitochondria all decreased. However, hyperventilation appeared to be the primary adaptation that defended the maximum oxygen uptake.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115154     DOI: 10.1016/s0196-0644(87)80746-1

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  4 in total

1.  Altitude-related illness: advice to travellers.

Authors:  R A Crutcher
Journal:  Can Fam Physician       Date:  1990-07       Impact factor: 3.275

2.  Operation Everest II.

Authors:  Peter D Wagner
Journal:  High Alt Med Biol       Date:  2010       Impact factor: 1.981

3.  Acute and chronic hypoxia: implications for cerebral function and exercise tolerance.

Authors:  Stuart Goodall; Rosie Twomey; Markus Amann
Journal:  Fatigue       Date:  2014

4.  Operation Everest II: resistance and susceptibility to chronic hypoxia in man.

Authors:  J T Reeves; C S Houston; J R Sutton
Journal:  J R Soc Med       Date:  1989-09       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.